Antibacterial Nanozyme Sustained-Release System Based on Arginine Carbon Dots within Zeolitic Imidazolate Frameworks
Source abstract
Abstract
Chronic wounds are susceptible to bacterial aggregation, which could lead to severe infections and a complicated healing process. Addressing bacterial infections is crucial for effective wound repair. In this study, we developed an antibacterial nanozyme sustained-release system, Arg-CDs/ZIF-8, by doping arginine carbon dots (Arg-CDs) into the zeolitic imidazolate framework (ZIF-8) to achieve pH-responsive release. ensuring prolonged action at the wound site. In the presence of hydrogen peroxide, Arg-CDs/ZIF-8 demonstrates superior generation of NO and reactive oxygen species capability, exhibiting promising synergistic antibacterial effects against E. coli and S. aureus . In vivo animal experiments also demonstrated the excellent wound-healing ability of Arg-CDs/ZIF-8 in the presence of H 2 O 2 . The in vivo toxicity results confirm that Arg-CDs/ZIF-8 has good biosafety, providing a promising nonantibiotic approach to combat wound infections, and highlighting its potential in the development of antimicrobial materials.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Nanomaterials in Catalysis · Carbon and Quantum Dots Applications · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Chemistry and Chemical Engineering
Yangzhou University
Department of Biomedical Engineering
City University of Hong Kong
College of Environmental Science and Engineering
Funding
Natural Science Foundation of Jiangsu Province · The Graduate Student Innovation Foundation of Jiangsu Province · Young scientists lifting project of Jiangsu Province, China
References (34)
Show source-provided references
1. 10.1038/s41598-024-70490-810.1038/s41598-024-70490-8 ↗
2. 10.3389/fchem.2021.68766010.3389/fchem.2021.687660 ↗
3. 10.3390/antibiotics1103039010.3390/antibiotics11030390 ↗
4. 10.1016/j.ijbiomac.2024.13458210.1016/j.ijbiomac.2024.134582 ↗
5. 10.1021/acs.accounts.9b0014010.1021/acs.accounts.9b00140 ↗
6. 10.1038/s41467-024-45255-610.1038/s41467-024-45255-6 ↗
7. 10.1021/acsanm.3c0052810.1021/acsanm.3c00528 ↗
8. 10.1016/j.jece.2021.10682110.1016/j.jece.2021.106821 ↗
9. 10.2174/138161282566619121615094810.2174/1381612825666191216150948 ↗
10. 10.1039/c2cs15272j10.1039/c2cs15272j ↗
11. 10.1016/j.ccr.2023.21505210.1016/j.ccr.2023.215052 ↗
12. 10.1002/advs.20230325910.1002/advs.202303259 ↗
13. 10.1016/j.cej.2022.13651210.1016/j.cej.2022.136512 ↗
14. 10.1002/sstr.20230000410.1002/sstr.202300004 ↗
15. 10.1021/acsami.3c0060310.1021/acsami.3c00603 ↗
16. 10.1016/j.actbio.2021.09.05110.1016/j.actbio.2021.09.051 ↗
17. 10.1039/D2DT01414A10.1039/D2DT01414A ↗
18. 10.1016/j.dyepig.2024.11209910.1016/j.dyepig.2024.112099 ↗
19. 10.1246/cl.21061910.1246/cl.210619 ↗
20. 10.1016/j.colsurfb.2020.11112710.1016/j.colsurfb.2020.111127 ↗
21. 10.3390/nano911157910.3390/nano9111579 ↗
22. 10.1039/D1RA02873A10.1039/D1RA02873A ↗
23. Gao J. · J. Mol. Sci. · 2018 · 34 · 324
24. 10.1021/acsomega.4c0244610.1021/acsomega.4c02446 ↗
25. 10.1016/j.msec.2021.11222510.1016/j.msec.2021.112225 ↗
26. 10.1016/j.cej.2015.02.09410.1016/j.cej.2015.02.094 ↗
27. 10.1007/s11999-014-3538-510.1007/s11999-014-3538-5 ↗
28. 10.1016/j.mattod.2015.11.00810.1016/j.mattod.2015.11.008 ↗
29. 10.1021/acsami.4c0239610.1021/acsami.4c02396 ↗
30. 10.1016/j.cclet.2023.10943010.1016/j.cclet.2023.109430 ↗
31. 10.1021/acs.analchem.0c0214910.1021/acs.analchem.0c02149 ↗
32. 10.1021/acs.analchem.3c0183010.1021/acs.analchem.3c01830 ↗
33. 10.1016/S0014-5793(02)02807-710.1016/S0014-5793(02)02807-7 ↗
34. 10.1002/adfm.20220285710.1002/adfm.202202857 ↗